JaLCDOI 10.18926/AMO/55863
FullText URL 72_2_197_n.pdf
Author Takase, Ken| Kada, Akiko| Iwasaki, Hiromi| Yoshida, Isao| Sawamura, Morio| Yoshio, Nobuyuki| Yoshida, Shinichiro| Iida, Hiroatsu| Otsuka, Maki| Takafuta, Toshiro| Ogata, Yuko| Suehiro, Youko| Hirabayashi, Yukio| Hishita, Terutoshi| Yoshida, Chikamasa| Ito, Takuo| Hidaka, Michihiro| Tsutsumi, Ikuyo| Saito, Akiko M.| Nagai, Hirokazu|
Abstract Standard therapy for idiopathic thrombocytopenic purpura (ITP) has not been established. We are conducting a multicenter, prospective trial to determine the efficacy and safety of short-term, high-dose dexamethasone therapy in ITP patients aged 18-80 years with platelet counts of <20, 000 /μL, or with <50, 000/ μL and bleeding symptoms. The primary endpoints of this trial are the proportion of responses (complete plus partial response) on day 180 (day 46+180) after the completion of the 46-day high-dose dexamethasone therapy. The results of this investigation of the effectiveness and safety of this regimen will be essential for the establishment of standard therapy for ITP.
Keywords idiopathic thrombocytopenic purpura short-term high-dose dexamethasone therapy open-label single-arm trial
Amo Type Clinical Study Protocol
Published Date 2018-04
Publication Title Acta Medica Okayama
Volume volume72
Issue issue2
Publisher Okayama University Medical School
Start Page 197
End Page 201
ISSN 0386-300X
NCID AA00508441
Content Type Journal Article
language 英語
Copyright Holders CopyrightⒸ 2018 by Okayama University Medical School
File Version publisher
Refereed True
PubMed ID 29674771